A Randomized Placebo-Controlled Safety and Pharmacodynamic Study of KB002, an Anti-GM-CSF Monoclonal Antibody, in Patients with Persistent Symptomatic Asthma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 22 Sep 2017

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

07 Aug 2017 According to a Humanigen media release, KaloBios Pharmaceuticals changed its name to Humanigen.
22 May 2013 Results presented at the 109th International Conference of the American Thoracic Society.
26 Feb 2013 Results presented at the 69th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com